Jason Christiansen, Ph.D.

Chief Technology Officer

Jason Christiansen, Ph.D., has served in multiple leadership positions developing new technologies and strategies for their research, diagnostic use and targeted therapy development. Jason joins Boundless Bio from Roche Sequencing Solutions where he was the head of assay development, providing leadership in initiatives around oncology testing, diagnostics development, NIPT testing and platform development. Prior to Roche, Jason was vice president of diagnostics at Ignyta, where he led CDx development efforts including an in-house CLIA laboratory and molecular testing R&D group working both internally and externally to drive molecular testing in support of a global clinical trial for Rozlytrek (entrectinib). These efforts produced one of the earliest Expedited Access Pathway (Breakthrough Diagnostic) designations for the Ignyta RNA next generation sequencing test.  After the purchase of Ignyta by Roche/Genentech, Jason contributed to integration efforts to define an updated global companion diagnostic strategy for Rozlytrek (entrectinib). As the senior director of assay development at Genoptix (Novartis), Jason led efforts to introduce new technology products, such as NGS and digital pathology, into the clinical laboratory for commercial and pharma applications. This included playing a role in the integration team for the purchase of HistoRx. At HistoRx, Jason was a leader in efforts to develop a quantitative immunofluorescence imaging platform, including assay, hardware, and software components, for clinical diagnostic testing and pharma applications.

Jason previously served in roles of increasing responsibility focusing on assay development and automation at Protedyne and Molecular Staging (acquired by Qiagen). Jason holds a B.S. in physics from the University of California, Davis and a joint Ph.D. in Biophysics from UC Davis and Lawrence Berkeley National Laboratory.

“At Boundless Bio, we are bringing together the latest technology and the brightest people to create innovative solutions for developing therapeutics and better understanding of the biology of ecDNA to save patient’s lives. To accomplish this, we work with passion, urgency and commitment to achieve the unprecedented.”